BRIEF published on 11/17/2025 at 07:05, 3 months 5 days ago Sandoz Launches First MS Biosimilar TYRUKO® in US Multiple Sclerosis Biosimilar Sandoz TYRUKO® Natalizumab
BRIEF published on 11/17/2025 at 07:05, 3 months 5 days ago Sandoz lance le premier biosimilaire de la sclérose en plaques, TYRUKO®, aux États-Unis. Sclérose En Plaques Biosimilaire Sandoz TYRUKO® Natalizumab
BRIEF published on 11/17/2025 at 07:05, 3 months 5 days ago Siegfried AG Announces CFO Transition Pharmaceutical Industry CFO Transition Siegfried AG Tania Micki Reto Suter
BRIEF published on 11/17/2025 at 07:05, 3 months 5 days ago Siegfried AG annonce un changement de directeur financier Industrie Pharmaceutique Transition Du Directeur Financier Siegfried AG Tania Micki Reto Suter
BRIEF published on 11/17/2025 at 07:05, 3 months 5 days ago Cicor Secures Major Orders and Expands with Valtronic Acquisition Acquisition European Market Order Intake Aerospace & Defence Valtronic Sites
BRIEF published on 11/17/2025 at 07:05, 3 months 5 days ago Cicor décroche d'importantes commandes et se développe grâce à l'acquisition de Valtronic. Acquisition Marché Européen Prise De Commande Aérospatiale Et Défense Sites Valtronic
BRIEF published on 11/17/2025 at 07:05, 3 months 5 days ago Innate Pharma to Present at Jefferies Global Healthcare Conference Biotechnology Immunotherapy Innate Pharma Jefferies Conference Antibody Therapeutics
BRIEF published on 11/17/2025 at 07:05, 3 months 5 days ago Innate Pharma présentera ses travaux lors de la conférence mondiale sur les soins de santé de Jefferies. Biotechnologie Immunothérapie Innate Pharma Conférence Jefferies Thérapeutiques Par Anticorps
BRIEF published on 11/17/2025 at 07:05, 3 months 5 days ago Pluxee Maintient des Perspectives Prudentes pour 2026 Suite à une Réforme au Brésil Interopérabilité Action En Justice Pluxee Perspectives 2026 Réforme Brésil
BRIEF published on 11/17/2025 at 07:05, 3 months 5 days ago Pluxee Maintains Cautious Outlook for 2026 Following Reform in Brazil Interoperability Legal Action Outlook 2026 Pluslee Brazil Reform
Published on 02/21/2026 at 00:45, 1 day 18 hours ago Bocana Resources Corp. Extends Letter of Intent on Arizona Mining Claims for Additional Bulk Testing and Assay Review
Published on 02/21/2026 at 00:30, 1 day 18 hours ago Redwood AI Corp. Announces Engagement for IR Services
Published on 02/20/2026 at 23:00, 1 day 19 hours ago Infinico Metals Corp. Announces Effective Date for 15-for-1 Common Share Consolidation
Published on 02/20/2026 at 22:17, 1 day 20 hours ago Organto Foods Completes Warrant Exercise Incentive Program
Published on 02/22/2026 at 12:19, 6 hours 28 minutes ago Elmos Semiconductor SE: Generational change initiated in the Supervisory Board
Published on 02/22/2026 at 10:09, 8 hours 38 minutes ago Turkiye Garanti Bankasi A.S.: Regarding the Sale of Non-Performing Loans Portfolio
Published on 02/21/2026 at 12:00, 1 day 6 hours ago Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Published on 02/21/2026 at 12:00, 1 day 6 hours ago Abivax présente, au Congrès de l’ECCO 2026, les premières preuves d’une activité antifibrotique d'obefazimod, ainsi que de nouvelles analyses de son efficacité et de sécurité dans les MICI
Published on 02/20/2026 at 18:36, 2 days ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 19:29, 1 day 23 hours ago SFPI GROUP: bilan du contrat de liquidité S2 S025
